The ethicolegal framework relevant to human  faecal microbiota transplants in South Africa: Part 2. Human stool as tissue? by Labuschaigne, M et al.
816       August 2020, Vol. 110, No. 8
RESEARCH
Faecal microbiota transplantation (FMT) has been shown to be 
an effective treatment for Clostridioides difficile infection (CDI) 
and has recently been incorporated into treatment guidelines for 
recurrent CDI in the USA and Europe. In South Africa (SA), a 
limited number of patients have been treated for recurrent CDI. 
FMT involves the introduction of microbiota from a healthy donor 
to a patient by colonoscopy, enema or a nasogastric tube with the 
aim of correcting or repairing a perturbed or dysbiotic microbial 
community.[1] Alternatively, patients may take capsules containing 
frozen donor bacteria orally. Capsular delivery of FMT was shown 
to be 96% effective in treating  CDI in one study, with similar 
efficacy rates to colonoscopic delivery, provided an adequate dose 
is administered via the capsular administration.[2] FMT capsules 
may vary by manufacturer; however, they usually have no scent or 
taste. Some capsules contain a donor-derived faecal slurry, while 
others comprise lyophilised bacteria.[3,4] Typically, the microbiota is 
encapsulated within an enteric-coated capsule to enable post-pyloric 
delivery.
Capsules have some advantages over colonoscopy in that they are 
non-invasive, without any of the risks associated with procedural 
sedation, and can be administered in a doctor’s office, with the 
patient required to take between 10 and 40 capsules within 1 hour.[2,4,5] 
Delivery of an FMT, whether using a faecal slurry via the colonoscope 
or nasoduodenal tube or through the use of capsules, points to two 
different regulatory frameworks: the transplant of human biological 
material on the one hand, and the regulation of medicines on the 
other. The legislative framework for the transplantation of human 
stool as tissue will be the focus of this article.
Although FMT is not new, it has recently gained more attention as 
a novel and effective treatment for recurrent CDI. In addition, FMT 
is currently being investigated in the treatment of other microbiome-
mediated diseases, ranging from inflammatory bowel disease to 
metabolic diseases, obesity, malnutrition and autism spectrum 
disorders.[1] In 2015, the South African Gastroenterology Society 
published a limited guideline on faecal microbiota transplants. The 
field has evolved significantly since these initial guidelines were 
published. At present, the regulatory framework surrounding FMT 
in SA remains unclear.
The purpose of this article is to explore the regulatory framework 
that applies to the regulation of human stool for the purpose of FMT. 
Exploring the legal framework governing human stool would require 
an analysis of human stool and its classification as ‘tissue’ in terms of 
the National Health Act 61 of 2003 (NHA).
Human stool as ‘tissue’ in terms of  
the NHA
Chapter 8 of the NHA governs the control of the use of human blood, 
blood products, tissue and gametes. Tissue is defined in section 1 as 
‘human tissue, and includes flesh, bone, a gland, an organ, skin, bone 
marrow or body fluid, but excludes blood or a gamete’. Human stool 
is not included but neither is it excluded, and for the purposes of this 
article we assume that stool is tissue. Tissue may only be removed 
from a living person with the informed consent of the donor, 
obtained in the prescribed manner and in accordance with prescribed 
conditions (section 55).
The Act stipulates in section 56 that the removed tissue may only 
be used for such ‘medical or dental purposes as may be prescribed’, 
but prohibits, among other things, the removal of tissue from a 
person who is mentally ill in terms of the Mental Health Care Act 
17 of 2002, as well as from a minor, if such tissue is not naturally 
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replaceable. Human stool is naturally replaceable and therefore 
minors should be able to donate, as they are legally allowed to 
donate other tissue from the age of 16. The prohibition of the use 
of stool from persons who are mentally ill in terms of the Mental 
Health Care Act is supported by the exclusion of stool donors with a 
personal history of neurological and neurodegenerative disorders, or 
psychiatric conditions.[6]
The regulations on the use of human biological material 
promulgated in terms of the NHA[7] do not refer to ‘tissue’ but use 
the phrase ‘biological material’ instead. The latter is defined as 
‘material from a human being including DNA, RNA, blastomeres, 
polar bodies, cultured cells, embryos, gametes, progenitor stem cells, 
small tissue biopsies and growth factors from the same’ (emphasis 
added). Although human stool samples would technically be covered 
by the scope of both definitions of ‘tissue’ and ‘biological material’, 
the Act refers to the ‘removal’, ‘withdrawal’ or ‘harvesting’ of the 
tissue (sections 55, 56, 59 and 68), whereas the regulations refer 
to ‘removal’ or ‘withdrawal’ only. Semantically, although the terms 
‘withdrawal’ and ‘removal’ may not fit the way stool samples are 
donated and collected for the purpose of FMTs as opposed to the 
removal of other types of tissue for transplantation, the focus is 
on the donation of the stool and its subsequent processing or use 
in FMT. The NHA provides that the ‘removal’ or ‘withdrawal’ of 
human biological material in terms of the regulations may only be 
performed by a ‘competent person’, defined as ‘trained’, and apply 
to specific health professionals involved in the withdrawal of blood, 
removal of gametes and fetal tissue, etc. If removed for ‘therapeutic 
purposes’, the tissue or biological material may only be ‘removed’ 
in an ‘authorised’, ‘prescribed’ or ‘prescribed research institution’ 
(regulation 2). Applying these legal requirements to FMT would 
mean that the collection of human stool (e.g. including the donation 
thereof) should take place in an authorised or prescribed institution. 
The requirement of the removal of stool by a ‘competent person’ is 
clearly redundant. Although donors were allowed to donate stool at 
home prior to 2018, the US Food and Drug Administration (FDA) 
now requires the donation to take place on site.
If human stool is considered ‘tissue’ in terms of the NHA, the 
storage, testing and processing of the stool for administration 
(transplantation) should comply with the relevant quality 
management, safety systems and traceability requirements for tissue 
banks in terms of the regulations relating to tissue banks,[8] which 
include standard operating procedures, the keeping of donor records, 
information on the final destination of tissues, etc.
The clinical administration (transplantation) of the faecal 
microbiota is very specific, with each route of administration (e.g. 
enema, colonoscopy, nasogastric) requiring adherence to approved 
and recognised clinical standards or guidelines. In SA, however, 
the absence of comprehensive regulations pertaining to tissue 
transplantation, including organ transplantation, creates significant 
obstacles for clinicians in the field of tissue and organ transplantation. 
These practitioners currently have to rely on wholly inadequate 
provisions in the NHA and existing regulations governing tissue 
transplantation. The NHA does not define what ‘transplantation’ is, 
but the tissue bank regulations describe it as ‘the transfer of allograft 
cells and/or tissue to a recipient’, which includes ‘musculoskeletal, 
skin, cardiovascular, and foetal cells and/or tissue’, which would cover 
FMT.
Should one accept that the use of human stool samples as part of 
FMT is covered by chapter 8 of the NHA as ‘tissue’ and ‘biological 
material’ in terms of the regulations, this would mean that the 
collection of the stool samples for ‘therapeutic purposes’ (such as 
a transplant) would need to comply with the above requirements. 
This necessitates a brief explanation of how the collection of stool 
samples for the purpose of FMT is performed in clinical practice. 
Based on the US FDA recommendations and the experience of a large 
US stool bank, it may include on-site stool donation and laboratory 
processing of material within a specified timeframe, usually within 2 
hours after passage.[9]
The person who intends to donate a stool sample must undergo a 
medical examination and submit to blood and stool tests. Prior to this, 
the potential donor will also need to complete a lengthy questionnaire, 
similar to blood donation questionnaires, aimed at identifying 
infectious disease risk factors associated with the microbiome. 
Donors are excluded for many reasons throughout the four stages of 
eligibility (online prescreening survey, clinical assessment, stool and 
nasal screening and blood tests).[10] Examples of reasons for exclusion 
as a donor include a history of exposure to systemic antibiotics 
in the past 6 months; being immunocompromised; tattooing or 
body piercing in the past 6 months, owing to increased infection 
risk; history of drug use or high-risk sexual behaviour; a history of 
incarceration; travel to areas with a high risk of endemic infectious 
disease; a history of chronic gastrointestinal disorders; and a history 
of autoimmune disease or malignancy.[10] Current studies highlight 
considerable variability in donor eligibility rates, ranging from 2% 
to 32%, despite the use of similar screening programmes.[6] Notably, 
Kassam et al.[10] recently published the largest screening cohort to 
date, in which of 15 317 consecutive donor candidates, only 386 (3%) 
were found to be eligible after the screening process. This report 
highlights the rigorous screening required to ethicolegally govern 
FMT repositories.
An FMT is most commonly delivered by colonoscopy, or less 
frequently by a nasoduodenal tube. Colonoscopic delivery enables 
administration of a larger dose of material and is associated with the 
highest efficacy rate in CDI compared with nasoduodenal or enema 
delivery.[9] During the colonoscopic FMT delivery, the colonoscope is 
advanced through the entire colon. The material is instilled into the 
caecum or terminal ileum and allowed to coat the entire length of the 
large bowel through normal peristalsis.[9]
The transplantation of faecal material, also assuming that its 
collection is governed by chapter 8 of the NHA, requires that removal 
of the material, as well as the transplant thereof into a recipient, 
may only be for research or therapeutic purposes (section 64), and 
must be performed by a medical practitioner only (section 59), in 
a hospital or authorised institution (section 58(1)(a)), with written 
authority of the hospital or the medical practitioner in charge of 
clinical services of that hospital (section 58(1)(b)). The medical 
practitioner who provides information for consent may not be part 
of the transplant team (section 58(2)). In addition, section 60 of the 
NHA stipulates that it is an offence to receive payment for a donation, 
except ‘for the reimbursement of reasonable costs incurred by him or 
her to provide such donation’.
Considering the novelty of FMTs, should the transplant be 
considered experimental therapy, section 11 of the NHA requires 
the health establishment to inform the recipient of a stool transplant 
in the prescribed manner that the procedure is for experimental or 
research purposes or part of an experimental or research project and 
that the patient, his or her treating doctor, the head of the hospital 
and the relevant research ethics committee have provided prior 
written consent for such procedure. Chapter 9 of the NHA and the 
regulations relating to research with human participants[11] provide 
the requirements that a researcher must comply with in order to 
conduct research involving human participants. Regulation 2 of 
these regulations states that research involving human participants 
must at a minimum comply with the 2015 National Department of 
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Health (NDoH) Ethics in Health Research guidelines for unproven 
interventions in clinical practice.[12] By incorporating the NDoH’s 
ethical guidelines into the research regulations, the ethical guidelines 
have the force of law and are hence legally binding. The protection 
of research participants in instances where research is conducted on 
human tissue is governed by regulation 17 of the regulations relating 
to tissue banks.[8]
Scientific experimentation and clinical trials, be they therapeutic 
or non-therapeutic, or beneficial to the patient or beneficial to others, 
are legally permissible provided they conform to the fundamental 
principles of informed consent to treatment and of emergency 
treatment, and to the duty of reasonable care, with considerations of 
public policy in the circumstances. Should an action for damages or a 
criminal charge flowing from harm allegedly suffered in consequence 
of improper or unacceptable experimentation arise, courts will be 
guided by the relevant ethical guidelines, such as the NDoH 2015 
Ethics in Health Research guidelines,[12] the guidelines on ethics for 
medical research of the South African Medical Research Council13] 
and the NDoH’s Guidelines for Good Practice in the Conduct 
of Clinical Trials (2006),[14] as well as generally acknowledged 
international codes and declarations on human experimentation and 
a wide range of international declarations on human rights in general.
Human stool banks as tissue banks
Currently human stool from patient-selected donors is used 
predominantly for clinical cases of FMT in SA. Should the treatment 
become more common, greater access to safe stool will be required. 
If, as argued above, it is assumed that human stool is tissue to fall 
within the ambit of the NHA, stool banks will be considered tissue 
banks. Tissue banks are regulated by the regulations relating to tissue 
banks in terms of the NHA.[8] The most important stipulations in 
these regulations are that a tissue bank needs to be authorised by the 
NDoH in order to ‘remove, acquire or import human tissue from 
any living or deceased person’ (regulation 2(1)(a)). A tissue bank 
must have a donor record management system in which the donor 
information is recorded, and the donor’s particulars are codified 
to protect anonymity. There should also be a quality management 
system in place to trace the donor stool from the recipient back to the 
original donor (regulation 6). Data necessary to ensure traceability 
should be kept for a period of 30 years after the donation (regulation 
14). The regulations also prescribe that there need to be standard 
operating procedures in place concerning the quarantine time, 
processing, storage, labelling and packaging of products (regulations 
9 - 16).
Stool banks (tissue banks) should comply with all the requirements 
stipulated in the regulations. There should also be a freezer in place to 
store the donations below 80oC and a sterilised separate room for the 
processing of the stools as requested by transplant practitioners. Stool 
banks should not be situated in close proximity to other tissue banks, 
as human stool contains many bacteria that should be separated 
completely from other human tissue, such as tendons and bones at 
a tissue bank.
Conclusions
In this article, we have argued that human stool fits the legal 
framework to be regarded as human tissue, despite the NHA’s lack 
of specificity on the status of human stool as tissue. Human stool 
donations are currently not addressed in any of the regulations in 
terms of the NHA, or in the Act itself. A new regulatory framework, 
such as regulations specifically dedicated to the use of human stool, 
is the ideal, but may take time to be effected.
In the meantime, and pending any further legal development 
regarding the use of stool, we argue that stool should be treated 
as tissue and therefore falls within the regulatory framework of 
current regulations regulating human tissue, including tissue banks. 
The classification of other types of human biological material for 
therapeutic purposes will soon be required. For example, vaginal 
microbiota transplantation (VMT) is a new treatment option for 
patients suffering from symptomatic, intractable and recurrent 
bacterial vaginosis.[15] Although outside of the focus of this article, 
VMT as a microbiome-based therapy will raise similar, though 
slightly different, considerations to FMT.
As stated above, faecal microbiota samples may also be processed 
into capsule form, to be orally administered. The legal framework for 
processed stool in the form of products requires further consideration, 
as the requirements, depending on the nature of the end product, 
may differ from those governing the administration of stool via 
colonoscopy or nasoduodenal tube discussed in this article. The legal 
position of a ‘faecal microbiota’ capsule or other more than minimally 
manipulated stool products will be highlighted in the third article 
in the series on the legal regulation of faecal microbiota transplants.
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